Control of meningococcal meningitis with meningococcal vaccines.
The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies.  Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity.  In controlled field trials in Army recruits, group C polysaccharide vaccines were highly effective in preventing group C disease.  Following its use as a routine immunization in recruits in October 1971 group C meningococcal disease has been almost completely eliminated from Army training centers.  Group A vaccine has been field tested in Egyptian school children with great success.  Group B polysaccharide has failed to induce bactericidal antibodies in humans and, therefore, new research is underway to attempt to develop a cell wall protein antigen as a vaccine against group B disease.
D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000032:analysis; D001770:Blood Bactericidal Activity; D006801:Humans; D007109:Immunity; D007223:Infant; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000517:prevention & control*; D008887:Military Medicine; D009345:Neisseria meningitidis / Q000276:immunology / Q000302:isolation & purification; D014481:United States; D014611:Vaccination; D014612:Vaccines / Q000592:standards*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D014612:Vaccines